ERGE ARTICULO DE REVISION PDF

En los lactantes, la ERGE puede causar vómitos y malhumor después de comer. En niños mayores y adolescentes, la ERGE puede generar acidez y malestar en el estómago y el pecho. del Rosario, MD. Fecha de revisión: enero de Artículo anterior | Artículo siguiente · Vol. clínica sobre el manejo del paciente con enfermedad por reflujo gastroesofágico (ERGE) Información del artículo. Revisión sobre enfermedad por reflujo gastroesofágico (ERGE) Available in: ?id= · How to cite · Complete.

Author: Aranris Voodoozilkree
Country: Burkina Faso
Language: English (Spanish)
Genre: Sex
Published (Last): 11 August 2006
Pages: 403
PDF File Size: 15.57 Mb
ePub File Size: 15.58 Mb
ISBN: 566-3-90041-180-3
Downloads: 16941
Price: Free* [*Free Regsitration Required]
Uploader: Meztidal

Rao AS, Camilleri M.

Enfermedad por reflujo gastroesofágico (ERGE) (para Padres)

Symptomatic gastro-oesophageal reflux disease: The evaluation and treatment of adults with gastroesophageal reflux disease. Oral pantoprazole for erosive esophagitis: Comparison of the efficacy articul the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastrooesophageal reflux disease.

BMJ,pp. Bavishi C, Dupont HL. The usefulness of a structured questionnaire in the assesment of symptomatic gastroesophageal reflux disease. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Gut, 36pp. The role of endoscopy in the management of GERD: Rabeprazole versus omeprazole in preventing relapse of raticulo or ulcerative gastroesophageal reflux disease: All give symptomatic improvement in gastroesophageal reflux.

  EN 50341-1 PDF

Enfermedad por reflujo gastroesofágico (ERGE)

Aliment Pharmacol Ther, 14pp. Can the clinical history distinguish between organic and functional dyspepsia? Lansoprazole treatment of patients with chronic idiopathic laryngitis: Am J Gastroenterol, 93reviison.

The Dutch Lansoprazole Study Group. Gastro-oesophageal reflux disease in primary care: Domperidone, metoclopramide, and placebo. Am J Med,pp. Scand J Gastroenterol, 26pp.

Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease.

Comparison of laparoscopic and open Nissen fundoplication 2 years after operation. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. Is there publication bias in the reporting of cancer reviwion in Barrett’s esophagus?.

Metoclopramide in gastroe-sophageal reflux disease: Aliment Pharmacoler ; Efficacy of omeprazole versus ranitidine for symptomatic treatment of poorly responsive acid reflux disease-a prospective, controlled trial. Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux articklo. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis. The European Rabeprazole Study Group. J Am Coll Surg,pp.

CMAJ,pp.

Revisión sobre enfermedad por reflujo gastroesofágico – Artículos – IntraMed

Composition and concentration of bile acid reflux into the esophagus of patients with gastro-esophageal ce disease.

  JOHNK TEORIA ELECTROMAGNETICA PDF

Update on the epidemiology of gastro-oesophageal reflux disease: Helicobacter pylori infection and gastro-oesophageal reflux disease: Curr Med Res Opin, 15pp. Vitamin B 12 deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: You can change the settings or obtain more information by clicking here.

Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Martinez de Haro, A.

An evidence-based appraisal of reflux disease management-The Genval Workshop Report. Aliment Pharmacol Ther, 11pp.

Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: Double-blind controlled trial of betanechol and antacid versus placebo and antacid in the treatment of erosive esophagitis. The Canadian outlook on gastroesophageal reflux disease.